Indication creep: Physician beware;L'expansion des indications: Médecins, attention

CMAJ. Canadian Medical Association Journal

Volumn 177, Issue 7, 2007, Pages 697-699

  Hébert, Paul C ^a   Stanbrook, Matthew ^a   Sibbald, Barbara ^a   Straus, Sharon ^a   MacDonald, Noni ^a   Attaran, Amir ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; ERYTHROPOIETIN; GABAPENTIN; RISPERIDONE; SALBUTAMOL; DRUG;

ANEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIALYSIS; DRUG COST; DRUG MANUFACTURE; EDITORIAL; HEMOPHILIA; HUMAN; MEDICAL RESEARCH; PHYSICIAN; SCHIZOPHRENIA; SEIZURE; UNITED STATES; CLINICAL PRACTICE; DRUG APPROVAL; DRUG LABELING; POSTMARKETING SURVEILLANCE;

CLINICAL TRIALS; DRUG APPROVAL; DRUG LABELING; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 34748870723     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.071223     Document Type: Editorial

References (5)

1. Zarychanski R, Turgeon AF, McIntyre L, et al. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled triais. JAMC 2007;177(7):725-34.
2. Mitka M. FDA sounds alert on anemia drugs. JAMA 2007;297:1868-9.
3. Henney JE. Safeguarding patient welfare: Who's in charge? Ann Intern Med 2006;145:305-7.
4. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
5. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-6.